Streetbeat News

Analyst Ratings

BUD

Citigroup analyst Simon Hales has upgraded Anheuser-Busch InBev (NYSE:BUD) from Neutral to Buy, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:17 pm

ITGR

Truist Securities has maintained a Buy rating on Integer Holdings and increased the price target from $137 to $145, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:12 pm

IGMS

JP Morgan analyst Eric Joseph has downgraded IGM Biosciences from Neutral to Underweight and reduced the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:12 pm

IPG

JP Morgan analyst David Karnovsky has downgraded Interpublic Group of Companies (NYSE:IPG) from Overweight to Neutral and reduced the price target from $36 to $33.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:11 pm

IGMS

Truist Securities has downgraded IGM Biosciences from Buy to Hold and reduced its price target from $24 to $12.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:10 pm

CLX

Jefferies analyst Kaumil Gajrawala has upgraded Clorox (NYSE:CLX) from Hold to Buy and increased the price target from $174 to $187.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:08 pm

MXL

Susquehanna analyst Christopher Rolland has downgraded MaxLinear (NASDAQ:MXL) from Positive to Neutral and reduced the price target from $26 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:04 pm

ARTL

EF Hutton has initiated coverage on Artelo Biosciences with a Buy rating and set a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:03 pm

PRTA

Prothena Corp (NASDAQ:PRTA) has received mixed analyst ratings recently, with a range of price targets and opinions from bullish to somewhat bearish. The average price target has decreased slightly, and several analysts have adjusted their ratings and targets. Prothena's financial performance is strong, with significant revenue growth and high profitability metrics.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 1:01 pm

INCY

Incyte (NASDAQ:INCY) has been analyzed by 11 financial analysts, showing a range of opinions from bullish to bearish. The average 12-month price target has increased by 2.73% to $71.82. Analysts have adjusted their ratings and price targets, reflecting their views on Incyte's market performance. Despite a 9.34% revenue growth, Incyte faces challenges with a net margin of -42.6% and ROE of -10.6%.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 1:00 pm